Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAX-222 in Pediatric Early Onset SCN2A-DEE
NCT05737784Phase 2Active, not recruiting
- Sponsor
- Praxis Precision Medicines
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 2 trial of elsunersen in SCN2A developmental and epileptic encephalopathy (SCN2A-DEE), sponsored by Praxis Precision Medicines. Started Apr 2023; status: active, not recruiting.
02
Drugs
elsunersen
03
Conditions
SCN2A developmental and epileptic encephalopathy (SCN2A-DEE)
Beyond the preview
Go deeper on NCT05737784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737784.